Natera Genetic Testing

by Natera  · Based in United States → — A global leader in cell-free DNA testing
Maternal-Fetal Medicine Obstetrics & Gynecology Oncology
Website
Claim this tool
Is this the maker? Claim the company →

Natera offers various pricing options including insurance coverage, prompt-pay cash prices, and financial assistance programs. they are in-network with most national and regional healthcare plans, including medicare. patients can receive pre-test cost estimates.
Regulatory Status Disclosed

Overview

Natera provides AI-driven genetic testing and analysis across various clinical areas, allowing physicians to order tests and receive comprehensive reports for diagnostic and treatment planning. The company specializes in non-invasive, cell-free DNA (cfDNA) testing technology, with a focus on women’s health, cancer, and organ health. Natera’s proprietary technology combines novel molecular biology with bioinformatics software capable of detecting single molecules in blood samples. Their tests are clinically validated in over 400 peer-reviewed publications with over 3 million patients studied. Natera operates CAP-accredited and CLIA-certified laboratories in Austin, Texas, and San Carlos, California, and an ISO 13485-certified lab. They also have over 150 medical professionals on staff to provide expert support, ensuring clear and easy-to-understand test results.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Cell-free DNA (cfDNA) testing
  • AI-driven genetic testing and analysis
  • Comprehensive reports for diagnostic and treatment planning
  • Noninvasive tests
  • Clinically validated (400+ peer-reviewed publications, 3M+ patients)
  • CAP/CLIA-certified and ISO 13485-certified labs
  • Expert medical professional support (150+ staff)
  • EMR Integration with major systems (e.g., Epic Aurau2122, OncoEMRu00ae)
  • NateraConnect Provider Portal
  • Natera Academy Provider Education Hub

Use Cases

  • Characterize tumors, anticipate cancer risk, and evaluate treatment response (Oncology)
  • Identify risk of severe genetic conditions for families (Women's Health)
  • Inform early intervention for improved outcomes (Women's Health)
  • Detect organ injury early and inform treatment strategy (Organ Health)
  • Genomics for rare disease diagnosis (Rare Disease)
  • Molecular Residual Disease (MRD) detection and cancer recurrence monitoring

What Physicians Need to Know

LIS/LIMS Integration
Natera integrates with all major EHR systems, including being a founding member of the Epic Aurau2122 (Order and Results Anywhere) network, enabling bidirectional order and results integration. They also integrate their oncology testing portfolio into Flatiron Health's OncoEMRu00ae platform for seamless electronic ordering and results delivery. Natera utilizes the LabKey LIMS platform and supports integration with upstream/downstream systems, including instruments, data pipelines, and reporting tools, via APIs, file-based integrations, or middleware solutions.
Supported Assay Types
Natera specializes in cell-free DNA (cfDNA) testing across oncology, women's health, and organ health. Key tests include: n* **Oncology:** Signaterau2122 (molecular residual disease/MRD detection), Latitudeu2122 (tissue-free MRD), Alterau2122 (comprehensive genomic profiling), and Empoweru2122 (hereditary cancer test). n* **Women's Health:** Panoramau2122 (Non-invasive prenatal testing/NIPT for aneuploidies, microdeletions, and triploidy), Horizonu2122 (advanced carrier screening), Vistarau2122 (single-gene NIPT), and Anorau2122 (SNP-based array on POC). n* **Organ Health:** Prosperau2122 (transplant assessment for kidney, heart, and lung) and Renasightu2122 (kidney gene panel). n* **Rare Disease:** Zenithu2122 (Genomics for Rare Disease). nTheir technology primarily uses next-generation sequencing (NGS) and SNP-based analysis.
QC/QA Features
Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA). They employ Quality Engineers to support quality system processes, including internal and external audits (GCP sponsor, CLIA/CAP, ISO 13485). The quality team addresses non-conformances and corrective actions, performs statistical analysis, and ensures compliance with CLIA, FDA QMSR, ISO 13485, and HIPAA. Routine Quality Control tests are performed on incoming raw materials and reagents.
Result Interpretation AI
Natera is actively developing its multimodal AI foundation model platform in collaboration with NVIDIA to enhance precision medicine. Their AI solutions are built upon extensive longitudinal oncology datasets and include applications such as NeoSelectu2122 (for prioritizing neoantigens), NeoPredict (for predicting immunotherapy response), a Digital Patient Simulator (for treatment optimization and outcome prediction), and Real-Time Trial Matching. The Panorama NIPT also incorporates proprietary artificial intelligence analysis. Natera leverages AI, including Amazon Textract, for extracting insights from unstructured clinical documents.
Critical Value Alerts
Natera's Hereditary Cancer Alert Program (HCAP) automatically flags Signaterau2122 patients who meet testing guidelines, providing an opt-in monthly report to referring physicians and genetic counseling staff. This program aims to identify more patients who could benefit from hereditary cancer testing. Their EMR integrations are designed to ensure timely access to actionable insights, streamlining the delivery of results directly into clinical workflows.
Instrument Interfaces
Natera supports integration between its LabKey LIMS and various upstream/downstream systems, including laboratory instruments. They have experience with instrument integration via APIs, file-based methods, or middleware solutions. Natera has also partnered with Illumina for the supply of sequencing instruments (e.g., HiSequ00ae 2500) and consumables for their non-invasive prenatal testing.
Reference Range Intelligence
While not explicitly termed 'reference range intelligence,' Natera's genetic tests provide personalized reports categorizing results as 'Low Risk' or 'High Risk' for specific genetic conditions. The Panorama NIPT boasts high sensitivity and specificity, with a low false positive rate and high positive predictive value (e.g., >95% for Trisomy 21). Natera also informs clinicians when a Variant of Uncertain Significance (VUS) has been reclassified, providing updated guidance.
Turnaround Time Impact
For the Panorama NIPT, most results are returned to the physician within 5-7 calendar days from the date samples are received at the lab, though some anecdotal reports indicate 4-10 days. The Horizon carrier screening test typically has a turnaround time of approximately 1 week. Natera's Signatera test has demonstrated the ability to detect cancer recurrence up to 9 months earlier than standard imaging, enabling earlier and potentially more effective therapeutic interventions.
Physician Tip

For Natera Genetic Testing, physicians should leverage the comprehensive EHR integrations (e.g., Epic Aurau2122, OncoEMRu00ae) for streamlined ordering and direct receipt of results, which can significantly reduce administrative burden and accelerate access to actionable molecular insights. Utilize Natera's specialized genetic counseling services for both pre- and post-test consultations to help patients understand complex genetic information and navigate next steps. For oncology patients, consider the Hereditary Cancer Alert Program (HCAP) to identify those who meet testing guidelines for hereditary cancer. Be aware of the rapid turnaround times for NIPT (5-7 days) and carrier screening (approx. 1 week) to manage patient expectations and facilitate timely clinical decisions. The AI-driven insights, particularly in oncology, can aid in personalized treatment decisions and earlier detection of recurrence, potentially improving patient outcomes.

Natera offers robust integration capabilities, notably as a founding member of the Epic Aurau2122 network, which provides a secure, HIPAA-compliant connection for bidirectional order and results integration, bypassing traditional point-to-point HL7 integration. They also have a two-way integration with Flatiron Health's OncoEMRu00ae platform for oncology tests. Their LIMS (LabKey) is designed to integrate with various upstream and downstream systems, including laboratory instruments, data pipelines, and reporting tools, supporting workflow automation and data standardization. Natera's collaboration with NVIDIA is focused on integrating their unique longitudinal datasets with NVIDIA's high-performance computing platforms and AI frameworks to develop advanced AI models for diagnostics and therapeutics.

Details

Category Lab & Diagnostics, OB/GYN AI, Oncology AI
Pricing Natera offers various pricing options including insurance coverage, prompt-pay cash prices, and financial assistance programs. they are in-network with most national and regional healthcare plans, including medicare. patients can receive pre-test cost estimates.
  • Insurance accepted (in-network with most plans, including Medicare); Prompt-pay cash price available; Financial assistance programs (e.g., $149 or less for qualified patients); Interest-free payment plans
DeploymentService-based (lab testing with digital portals and EMR integration)
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status Cleared AI-estimated

While Natera's laboratory-developed tests (LDTs) have not been cleared or approved by the FDA, their Signatera test has received three FDA Breakthrough Device Designations. Natera has also submitted a premarket approval (PMA) for Signatera CDx, which, if approved, could be the first companion diagnostic MRD test to guide treatment decisions.
Integrations
EHR Not specified
Specialties Maternal-Fetal Medicine, Obstetrics & Gynecology, Oncology

What the Web Says

Natera offers specialized genetic tests in areas like reproductive health, oncology, and organ health, utilizing cell-free DNA analysis. These tests are generally considered reliable and accurate for targeted health information, backed by numerous peer-reviewed publications. However, the company faces significant criticism regarding its billing practices and customer service, with many patients reporting unexpected and high charges, even after being told tests would be covered by insurance or have a lower self-pay rate.

Overall: Negative

Strengths

  • Specialized and targeted genetic testing in reproductive health, oncology, and organ health.
  • Utilizes advanced cell-free DNA (cfDNA) analysis, a non-invasive method.
  • Tests are backed by over 250 peer-reviewed publications, indicating strong clinical research support.
  • High accuracy in detecting certain conditions like Down syndrome.
  • Offers financial assistance programs and interest-free payment plans.
  • Some users report positive experiences with accurate and timely results.

Limitations

  • Lack of transparent pricing, leading to unexpected and significantly higher bills than quoted.
  • Numerous complaints and class-action lawsuits regarding deceptive billing practices.
  • Poor customer service and difficulty resolving billing issues.
  • Reports of false positives and inconclusive results in prenatal tests, causing stress.
  • Limited scope of tests, not offering comprehensive whole-genome analysis or general wellness insights.
  • Issues with insurance claims, including lack of prior authorization and difficulty switching to self-pay after billing.

Based on reviews from: Nucleus, Reddit, Nebula Genomics, Better Business Bureau, Trustpilot, DNA Testing Choice

Last updated: 2026-07-22

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Natera Genetic Testing

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Investing.com
Natera enhances prenatal test, cuts no-call rate to 0.5%
Natera Inc. announced an enhancement to its Panorama non-invasive prenatal test, reducing the no-call rate to 0.5% through new SNP-informed deep sequencing technology. This improvement aims to enhance performance in samples with low fetal fraction, a condition that can make accurate prenatal screening more difficult.
2026-05
Business Wire (via Global Genes)
Natera Announces Commercial Launch of Zenithu2122 Genomics for Rare Disease Diagnosis
Natera launched Zenith genomics, a new whole genome sequencing assay designed to improve the detection of rare diseases and shorten diagnostic journeys for patients. The technology, developed by MyOme, provides enhanced resolution for hard-to-detect genetic features.
2026-03
Business Wire
Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine
Natera announced reaching over 300 peer-reviewed publications featuring its technology across oncology, women's health, and organ health. This milestone reinforces their commitment to clinical evidence and scientific research in precision medicine.
2025-08
ClassAction.org
Natera Facing Class Action Lawsuit Over Allegedly Misleading IVF Genetic Testing Claims
A class action lawsuit filed in June 2026 accuses Natera of deceptively marketing its Spectrum preimplantation genetic testing for aneuploidy (PGT-A) as highly accurate. The lawsuit alleges that Natera suppressed information about the test's true effectiveness, leading families to potentially discard viable embryos.
2026-06
Business Wire
EXPAND Trial of Natera's Fetal Focusu2122 Single-Gene NIPT Surpasses >2000 Patients Enrolled
Natera announced that its EXPAND clinical trial for the Fetal Focus single-gene noninvasive prenatal test (NIPT) has enrolled over 2,000 patients. The trial aims to expand the scope of NIPT for inherited conditions and features rigorous design with confirmed outcomes.
2026-05
Stock Titan
Signaterau2122 MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study
A study published in JAMA Dermatology found that Natera's Signatera test was a significantly stronger predictor of Merkel cell carcinoma recurrence than the AMERK test, detecting relapse earlier with higher sensitivity and predictive values.
2026-07
Business Wire
Natera Announces Expansion to 20 Genes for its Fetal Focusu2122 Single-Gene NIPT
Natera announced the expansion of its Fetal Focus single-gene noninvasive prenatal test (sgNIPT) to cover 20 genes. This advancement, utilizing Natera's LinkedSNPu2122 technology, is optimized for detecting challenging homozygous cases.
2025-10
Natera Press Release
Finalized MolDx LCD Includes Expanded Coverage for Natera's Prosperau2122 Portfolio
Natera announced that the MolDx Local Coverage Determination (LCD) has been finalized to include expanded coverage for its Prosperau2122 portfolio. This regulatory update is significant for the accessibility of Natera's organ health tests.
2026-07

Videos

Product demos, reviews, and walkthroughs for Natera Genetic Testing.

View all on YouTube

Frequently Asked Questions

Natera leverages AI and machine learning, particularly in its Panorama NIPT, to enhance probabilistic modeling and analyze cell-free DNA (cfDNA) data, building on its unique SNP-based platform. This AI integration has led to improved positive predictive value (PPV) for conditions like 22q11.2 deletion syndrome and a 50% reduction in no-call rates while maintaining high sensitivity for aneuploidies, ultimately increasing diagnostic accuracy and enabling earlier detection of conditions like cancer recurrence. Natera is also developing proprietary AI foundation models trained on extensive oncology datasets to drive innovation in therapeutic development, biomarker discovery, and clinical decision support.
Natera's laboratories are CLIA-certified and CAP-accredited, ensuring adherence to quality and validity standards for their tests. While Natera's laboratory-developed tests (LDTs) have not been cleared or approved by the FDA, CLIA certification is required to ensure their quality and validity. Furthermore, Natera is bound by HIPAA regulations to maintain the privacy of protected health information (PHI), and they state they do not sell patient PHI.
Alternatives to Natera's genetic testing include companies like Myriad Genetics, which offers clinical-grade testing for various conditions, including cancer, and may use standard cell-based DNA in addition to cfDNA. Other providers like LabCorp (MaterniT21), BilliontoOne (Unity test), and various AI genetic analysis tools such as DeepVariant and Bioconductor also offer genetic testing and analysis, with some integrating AI for variant calling and data analysis. While Natera specializes in cell-free DNA technology across oncology, women's health, and organ health, competitors may differ in their specific test offerings, technological approaches (e.g., whole-genome sequencing vs. targeted panels), and the extent of their AI integration.
Natera welcomes all insurance plans and is in-network with the vast majority, often resulting in insurance coverage and no out-of-pocket costs for over 60% of patients. For patients with out-of-pocket costs due to deductibles, copays, or coinsurance, Natera offers financial assistance programs, interest-free payment plans, and prompt-pay cash prices, which are typically $249 or $349 depending on the test. However, some consumers have reported receiving significantly higher bills than initial estimates, highlighting the importance of understanding specific insurance plan details and Natera's billing practices.
Natera's genetic tests, including those with AI-powered interpretations, are screening tests and do not provide a final diagnosis; high-risk results require diagnostic confirmation through methods like CVS or amniocentesis. While Natera's Panorama NIPT boasts high sensitivity (e.g., >99% for trisomy 21) and improved positive predictive value with AI, all prenatal genetic testing can have false positive and false negative results. Physicians should counsel patients that decisions about pregnancy should not be based solely on screening results and emphasize the need for confirmatory diagnostic testing for high-risk findings.
Natera is bound by HIPAA regulations and is committed to maintaining the privacy of protected health information (PHI). They explicitly state that they do not sell patient PHI or personal information collected as part of healthcare operations. When AI algorithms are involved, Natera trains its core AI foundation models on de-identified datasets, integrating genomic, clinical, and imaging modalities to protect patient confidentiality while enabling discovery.
Natera provides various support and educational resources for clinicians, including access to their NateraConnect Provider Portal and an extensive resource library with videos, webinars, and publications. They also offer complementary genetic counseling services, where Natera's genetic counselors can help providers understand individual test results and inform them of variant reclassifications. Additionally, Natera offers NEVA (Natera's Educational Virtual Assistant) which provides interactive results delivery and education for patients, and clinicians can access NEVA session transcripts on NateraConnect.

Related Tools

LabLynx AI-Powered LIMS
LabLynx
Lab & Diagnostics
LabLynx AI-Powered LIMS integrates AI and Machine Learning into laboratory information management systems to automate complex analyses, predict outcomes, and optimize workflows for various lab settings. The platform offers LIMS, ELN, and Lab Automation suites, providing configurable and scalable solutions for diverse laboratory needs.
August AI
August AI
Lab & Diagnostics
August AI offers an AI-enabled telehealth platform with an AI health chatbot and virtual care services, including telehealth visits and prescription management. The company's AI chatbot is available globally for free, providing information and not medical advice. In the U.S., August AI offers August Care, a membership that provides clinical services, discounted labs, and quick prescriptions.
$0 (chatbot) / $39 per visit / $39 per month (august care membership)
Allergios®
Allergios®
Lab & Diagnostics
Allergios® is developing an in-vitro diagnostic system that directly visualizes allergic responses in blood serum to provide unambiguous allergy diagnoses, starting with food allergies.
PNOĒ
PNOĒ
Endocrinology & Metabolic AI
PNOĒ is a science-backed cardiometabolic analyzer that performs comprehensive breath-based assessments to measure 23 biomarkers, including VO₂ max, resting metabolic rate (RMR), fat burn efficiency, and biological age. It delivers a 360° snapshot of an individual's physiology by analyzing how oxygen flows through the lungs, heart, and cells. The insights generated are used to personalize nutrition, exercise, and longevity plans.
Varies
Folklore Clinical Variant Interpretation
Helena Bioinformatics
Lab & Diagnostics
Folklore is a clinical variant interpretation platform for genetic laboratories and researchers that brings genomic annotation, ACMG/AMP classification, phenotype and inheritance evidence, literature, and structured reporting into one traceable workflow.
Freemium
Insitro
Insitro
Drug Discovery & Research
Insitro combines automated cellular experiments with population-scale genetics to build Physical AI systems that reveal causal drivers of human disease and deliver targeted therapeutics.

See all Lab & Diagnostics tools →

Suggest an Edit → | Last Verified: 2026-04-22 | First Added: 2026-04-22

Investors who backed Natera Genetic Testing

Funded through the company that built this tool.

Foresite Capital
VC T3
San Francisco, United States
$25M+
Foresite Capital is a healthcare-dedicated multi-stage investment firm with substantial assets under management, investing across drug development, medical devices, diagnostics, and healthcare…
AI/ML in Healthcare Biotech
AI Tool Finder
AI-powered search. Results may not be comprehensive.